Profile of safety and effectiveness dipeptidyl peptidase-4 inhibitors
Keywords:
Antidiabéticos, Diabetes Mellitus, Farmacovigilância.Abstract
Objective: To analyze the safety profile and effectiveness of antidiabetic drugs dipeptidyl peptidase-4 (DPP-4).
Methods: Articles were selected through a review in Portal de Periódicos Capes. The following descriptors were used: "saxagliptin", "sitagliptin", "linagliptin," "vildagliptin", "alogliptin", "dutogliptin" and "Dipeptidyl Peptidase-4 Inhibitors". The "AND" connector was used between the descriptors and the word "meta-analysis". The research or study was limited to publications in English, Spanish and Portuguese. Only meta-analyzes that contemplated parameters of safety and / or effectiveness of DPP-4 inhibitors were included.
Results: Based on 23 studies, it was observed that DPP-4 inhibitors showed a proven average reduction of glycated hemoglobin (HbA1c) from 0.6% to 0.93% compared to placebo. However, when the DPP-4 inhibitors were combined with metformin, glycemic control was more effective. It was also observed that the DPP-4 inhibitors are associated with reduced risk of bone fractures, the protective effect on plasma lipids and cardiovascular events. And yet, they were not associated with increased risk of pancreatic reactions. However, they are associated with higher incidence of urinary tract infections and nasopharyngitis.
Conclusion: In conclusion, the DPP-4 inhibitors are new and promising therapeutic options, since they have reduced risk of hypoglycemia. However, new longitudinal clinical studies with larger sample size are needed in order to confirm the associations identified in the selected meta-analyzes.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
